Skip to content
Company Analysis

Glaukos Corporation GKOS

A comprehensive view of key metrics, scores, and financial health for Glaukos Corporation

Overview of Glaukos Corporation

GKOS NYQ
Healthcare Medical Devices Framework: Medical Devices & Diagnostics Large Cap
Glaukos Corporation (GKOS), is a Large Cap company, in the Medical Devices industry, last closed at $238.61, about 96.9% overvalued vs fair value, +191.7% 1Y return, ranked 375/1145 in sector.
Metrics Rev Growth 32.3% ROE -26.4% Gross Margin 55.7%
USD 238.61
0.43%
(Delayed)
• Vol 90d: 60.8%
52-Week Range
Market Cap
$14.12B
Enterprise Value
$14.00B
Overall Score
View breakdown
Overall
Growth
Fair
Profitability
Good
Health
Fair
Efficiency
Fair
Valuation
Fair
Growth
Fair
Profitability
Good
Health
Fair
Efficiency
Fair
Valuation
Fair
Completeness: 82%
Confidence: 86%
Updated: Oct 31
Top Beats
No strong beats yet

Quick Facts

Website https://www.glaukos.com
HQ Aliso Viejo, CA
Employees 1,094
Fiscal year Dec 31

Next Events

No upcoming events available.

Fair Value Snapshot

Bear Base Bull
$6
$7
$9
Current: $238.61 -97% vs base

Engine Room Money Flow™

Large Cap

Medical Devices & Diagnostics - Where revenue goes and how value is created

Flow Steps
Total Revenue
$507.4M
32.3%%
Gross Profit
$282.8M
-2.3%%
Operating Income (GAAP)
-$199.6M
-63.1%%
EBITDA
-$146.1M
-52.7%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Medical Devices & Diagnostics

Quality & Reliability Indicators

Gross Margin
55.7%
Good

Gross Profit / Revenue — primary moat signal for MedTech. ≥65% indicates IP-protected consumables with strong pricing power.

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Where It Leaks

Cash Flow Health critical
Significant cash flow inefficiencies identified. Multiple high-impact leaks require attention.
1
Active Leaks
0/1
Improving
0
High Impact
1
Critical
Moat Analysis Medical Devices & Diagnostics

Competitive Advantage Assessment

Evaluating Glaukos Corporation's durable competitive advantages across 6 defense dimensions

Overall Moat Strength
50
/100
Moderate
Scores based on quantitative metrics and qualitative factors
Full moat analysis

Key strengths

  • Improving FCF Trend FCF trend score is positive (score 0.61). Improving FCF margin signals compounding operational leverage.
  • Durable Capital Returns ROIC durability is strong (score 0.65). Consistent returns confirm the moat is not eroding.

Key risks

  • Thin Interest Coverage Interest coverage lags peers (score 0.21). Thin coverage limits M&A optionality and raises refinancing risk.
  • Gross Margin Volatility Gross margin stability is poor (score 0.24). Margin volatility undermines the consumable moat thesis.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power & Consumable Moat

Developing
37
Premium

Signals, strengths and risks for Pricing Power & Consumable Moat

Premium

Signals, strengths and risks for R&D Pipeline & Capital Returns

Premium

Signals, strengths and risks for FCF Quality & Cash Conversion

Premium

Signals, strengths and risks for Commercial Execution

Premium

Signals, strengths and risks for Capital Structure & Resilience

Premium

Signals, strengths and risks for Growth Durability

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Healthcare: MedTech (Devices & Supplies) vs Industry Peers 83% Coverage
Trade-Off Triangle Visualization A ternary plot showing GKOS's balance between Growth (42.2%), Profitability (30.4%), and Safety (27.4%). Growth 42% Safety 27% Profitability 30%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

63th percentile vs peers
63
Key Signals
Rev Growth YoY 32.3% 86p Revenue CAGR 3Y 21.5% 75p EPS Growth YoY -18.3% 23p Asset Growth YoY -8.3% 27p
Strengths
  • Rev Growth YoY in top 20% of peers (32.3%, 86th percentile)
  • Growth above peer median with strong metric coverage (75%)
Risks

No significant risks identified for this axis.

Profitability

45th percentile vs peers
45
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

40th percentile vs peers
41
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Glaukos Corporation.

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$7.49
- - -
-96.9% vs current
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info
Send Feedback
Please select a category.
0/1000